Trial
NCT04119453
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Elevar Therapeutics
Collaborators
—
Condition
Adenoid Cystic Carcinoma
Intervention
Rivoceranib
Why stopped
The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development plan.
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-30